Dr. David M. Barrett Joins ProUroCare Board of Directors
November 05 2012 - 7:00AM
Business Wire
ProUroCare Medical Inc. (OCTQB: PUMD), a provider of proprietary
medical imaging products, today announced that Dr. David M.
Barrett, MD, was elected to ProUroCare’s Board of Directors at
their quarterly board meeting. He is the former President and CEO
of the Lahey Clinic in Burlington, Massachusetts, which is one of
the largest medical centers in New England. In addition to his
urology practice, Dr. Barrett currently sits on the Board of
Directors of Advantedge Healthcare Solutions, Inc., CR Bard Inc.,
Commonfund, Inc., Sapphire Systems, Inc. and Juliet Marine, Inc. He
is a Member of the Life Sciences Advisory Board of Safeguard
Scientifics, Inc. and is the former Chairman of the Massachusetts
Hospital Association.
“Dr. Barrett’s years of experience in leadership roles at the
nation’s top medical centers, his insights as a practicing
urologist and his extensive business and medical experience make
him an ideal candidate to help ProUroCare as we seek to
commercialize our mechanical imaging technology,” said Rick
Carlson, ProUroCare’s CEO. “Dr. Barrett is also uniquely qualified
to work with a developing medical products company that has a broad
technology platform from which numerous medical products can be
developed, helping us achieve our goal of transforming the
diagnosis, monitoring and management of prostate disease.”
“ProUroCare is an exciting early stage technology company,” said
Dr. Barrett. “I’m looking forward to working with Rick,
ProUroCare’s board and its numerous medical technology advisors and
key opinion leaders in urology to help build a truly great company
in the years ahead.”
Dr. Barrett is a Clinical Professor of surgery at the Dartmouth
Medical School and a staff urologist at the Dartmouth Hitchcock
Medical Center. Dr. Barrett began working at Mayo Clinic
(Rochester, Minnesota) as a staff physician in 1975. He was Chair
of the Department of Urology of Mayo Clinic, where he served on the
Board of Trustees and as Vice Chair of the Board of Governors. From
1970 to 1972, Dr. Barrett served as a flight surgeon during the
Vietnam War, and became Chief of the Aeromedical Service at Cam
Rahn Bay Air Base. He is a former Trustee at Albion College.
Dr. Barrett is an authority on urologic oncology, urinary
incontinence, bladder reconstruction, and genitourinary prostheses.
During the course of his career, he has been widely published in
academic journals and has received numerous research grants and
contracts. Among his many professional affiliations are memberships
in the American College of Surgeons, the American Urologic
Association, and the American College of Healthcare Executives. He
is a past president of the American Board of Urology. Dr. Barrett
received his B.A. from Albion College and his M.D. from Wayne State
University School of Medicine.
Dr. Barrett replaces retiring director David Koenig, who will
continue to act as ProUroCare’s Corporate Secretary. Dr. Barrett
will serve on ProUroCare’s Governance and Nominating Committee.
About ProUroCare Medical Inc.
ProUroCare Medical Inc. is a publicly traded company engaged in
the business of creating innovative medical imaging products. The
company’s ProUroScan system, an elasticity imaging technology used
to document abnormalities of the prostate previously detected by a
digital rectal examination, received commercial clearance from the
FDA on April 27, 2012. Based in Minneapolis, the company’s stock
trades on the OTCQB market (www.otcmarkets.com).
This news release contains certain "forward-looking" statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements are typically preceded by words such as
"believes," "expects," "anticipates," "intends," "will," "may,"
"should," or similar expressions. These forward-looking statements
are not guarantees of ProUroCare's future performance and involve a
number of risks and uncertainties that may cause actual results to
differ materially from the results discussed in these statements.
Factors that might cause ProUroCare's results to differ materially
from those expressed or implied by such forward looking statements
include, but are not limited to, the ability of ProUroCare to find
adequate financing to complete the development of its products; the
high level of secured and unsecured debt incurred by ProUroCare;
the impact and timing of actions taken by the FDA and other
regulatory agencies with respect to ProUroCare’s products and
business; the dependence by ProUroCare on third parties for the
development and manufacture of its products; and other risks and
uncertainties detailed from time to time in ProUroCare's filings
with the Securities and Exchange Commission including its most
recently filed Form 10-K and Form 10-Q. ProUroCare undertakes no
duty to update any of these forward-looking statements.
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Nov 2024 to Dec 2024
ProUroCare Medical (CE) (USOTC:PUMD)
Historical Stock Chart
From Dec 2023 to Dec 2024
